Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Monday

Syndax Pharmaceuticals (NASDAQ:SNDX) is anticipated to post its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect the company to announce earnings of ($0.4919) per share and revenue of $81.75 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 2, 2026 at 4:30 PM ET.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, August 4th. The company reported ($0.55) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.10). The business had revenue of $72.79 million during the quarter, compared to analysts’ expectations of $79.36 million. Syndax Pharmaceuticals had a negative return on equity of 372.94% and a negative net margin of 87.52%. Syndax Pharmaceuticals’s revenue for the quarter was up 91.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.83) EPS. On average, analysts expect Syndax Pharmaceuticals to post ($2.01) EPS for the current fiscal year and ($1.01) EPS for the next fiscal year.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $13.65 on Friday. The company has a quick ratio of 6.44, a current ratio of 6.77 and a debt-to-equity ratio of 38.95. The company has a market capitalization of $1.21 billion, a PE ratio of -5.44 and a beta of 0.42. The firm has a fifty day simple moving average of $17.18 and a two-hundred day simple moving average of $20.25. Syndax Pharmaceuticals has a twelve month low of $12.80 and a twelve month high of $25.59.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Syndax Pharmaceuticals in a research note on Tuesday, October 13th. Weiss Ratings lowered Syndax Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, October 19th. Bank of America reissued a “buy” rating on shares of Syndax Pharmaceuticals in a research note on Wednesday, August 5th. UBS Group restated a “buy” rating on shares of Syndax Pharmaceuticals in a report on Thursday, October 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Syndax Pharmaceuticals in a research report on Tuesday, September 29th. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $41.80.

Insider Buying and Selling

In related news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction on Thursday, October 29th. The shares were sold at an average price of $14.21, for a total transaction of $113,680.00. Following the completion of the sale, the director directly owned 239,763 shares in the company, valued at $3,407,032.23. This represents a 3.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 4.80% of the stock is owned by corporate insiders.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.